Petrichor Healthcare Capital Management

Managing Partner Tadd Wessel leads the firm. He is supported by Partners Patrick Lally and Michael Beecham within Petrichor Capital Partners. For the Scion Life Sciences vehicle, Samuel Hall and Aaron Kantoff serve as founding managing partners and drive venture-creation decisions. The firm's website emphasizes a collaborative model built on deep scientific and commercial expertise across its leadership.

Scion Life Sciences is a dedicated venture capital fund for founding and building new biotechnology companies. It seeks clinically transformative or curative medicines and explicitly avoids incremental advances. Petrichor Capital Partners, by contrast, invests across private and public companies in biopharma, medical technology, and services at later development and commercial stages.

Petrichor's platform spans company formation through late-stage growth. Scion Life Sciences handles the earliest stage — company creation. Petrichor Capital Partners covers expansion, late-stage, and commercial growth, including public-company investments. The firm's website confirms this full lifecycle approach but does not break out a minimum or maximum check size.

Petrichor relies on its in-house team of scientists, physicians, and operators to identify opportunities rather than a traditional agent-driven origination model. By embedding expertise in biopharmaceutical product development, regulatory pathways, and medical technology commercialization, the firm aims to spot and create investment opportunities before they are broadly marketed to other funds.

The firm does not publicly describe itself as a fund-of-funds. Its disclosed vehicles — Petrichor Capital Partners and Scion Life Sciences — both appear to execute direct investments and company formation. There is no reference to investing in third-party funds, though a lack of detailed portfolio disclosures makes it difficult to rule out co-investment alongside other managers.